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1. Introduction 
Gastroenteritis is globally responsible for great morbidity and mortality among all ages. In 
the developing countries, it still represents one of the top causes of death for children <5 
years of age, resulting in 1,8 million fatalities every year (Boschi-Pinto et al., 2008; Bryce et 
al., 2005). Viruses are responsible for the majority of cases of gastroenteritis with rotaviruses 
and noroviruses being the major pathogens.  
Noroviruses are today recognized as the leading cause of foodborne outbreaks and sporadic 
cases of gastroenteritis worldwide (Glass et al., 2009; Patel et al., 2009). Nowadays, they are 
even considered the second most important agent of severe childhood diarrhea after 
rotavirus (Koopmans, 2008; Patel et al., 2008; Ramani & Kang, 2009) but the importance of 
norovirus in this age group is expected to increase in the upcoming years, as a consequence 
of the implementation of routine rotavirus vaccination (Koo et al., 2010).  
The recognition of the clinical importance of norovirus only began in the late 1990s when 
sensitive routine diagnostic methods became available. In fact, the first norovirus (the 
Norwalk virus) was discovered in 1972 (Kapikian et al., 1972) but more than twenty years 
were necessary to disclose the important role of these viruses as human pathogens. 
Noroviruses are now on the upswing and a fundamental question is being raised: are 
norovirus really emerging? (Widdowson et al., 2005) 
Despite the increasing attention given to norovirus today and the significant morbidity and 
mortality associated with norovirus gastroenteritis, no specific antiviral drugs or vaccines are 
yet available for treatment or prevention of norovirus illness. Only recently, a recombinant 
intranasal vaccine has entered a phase I clinical trial (El-Kamary et al., 2010; Vinje, 2010) 
This chapter will highlight the importance of finding specific antiviral therapy for norovirus 
infection and explore biological features of norovirus, pointing out directions to stop or 
control this important human pathogen. 
1.1 Clinical disease, transmission and epidemiology 
Norovirus gastroenteritis is generally acute and self-limited, but in infants, elderly, and 
immunocompromised individuals it may be more severe and prolonged since they are more 
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susceptible to complications due to dehydration (Green, 2007; Patel et al., 2008). After an 
incubation period of 24–48 h, there is an acute onset of symptoms of nausea, vomiting, 
abdominal cramps, myalgias, and intense non-bloody diarrhea which usually resolves in 2–
3 days (Green, 2007). The median duration of illness can be longer, lasting up to six weeks in 
infants and young children (Kirkwood & Streitberg, 2008; Murata et al., 2007; Patel et al., 
2009). Prolonged shedding is also documented in transplant patients and other 
immunosuppressed individuals, with symptoms lasting over two years (Hutson et al., 2004; 
Widdowson et al., 2005). Deaths have been reported in elderly during outbreaks in nursing 
homes, hospitals and cruise ships (Gotz et al., 2002; Lopman et al., 2004; Patel et al., 2008). 
Repeated associations of norovirus infections with clinical outcomes other than 
gastroenteritis have been reported (CDC, 2002; Chen et al., 2009; Kawano et al., 2007; 
Marshall et al., 2007; Turcios-Ruiz et al., 2008). Moreover, norovirus RNA has been detected 
in the blood of children with norovirus gastroenteritis and in the cerebrospinal fluid of a 
child with encephalopathy (Ito et al., 2006; Takanashi et al., 2009). This data suggests that 
norovirus infection is probably not limited to the intestine and could disseminate to 
systemic sites.  
Noroviruses are transmitted by the fecal-oral route either directly from person-to-person or 
indirectly through consumption of contaminated food (fresh fruit, vegetables, shellfish and 
bakery products), water (drinking, ice or swimming) or following exposure to contaminated 
environmental surfaces and to airborne vomitus droplets (Green, 2007). Concerns about a 
potential zoonotic transmission have been raised given the close genetic relatedness 
between norovirus found in humans and animals and the presence of antibodies to animal 
strains in humans (Bank-Wolf et al., 2010). 
Norovirus outbreaks are notably extensive and often occur in semi-closed environments 
(nursing homes, hospitals, day-care centers, schools, cruise ships and restaurants) that favor 
person-to-person transmission (Glass et al., 2009; Patel et al., 2009). Moreover, modern 
lifestyles make people more vulnerable to norovirus. More elderly people and infants live in 
communal settings, people eat more food outside the household (handled by potentially 
infected workers), consume more imported fresh fruit and vegetables from countries where 
crops are still irrigated with sewage-contaminated water and also more people are travelling 
and being exposed to norovirus in hotels, airplanes and cruise ships (Widdowson et al., 
2005). 
The very low infectious dose of norovirus (≈ 17 virus particles), their long persistence in the 
environment, withstanding sanitary measures effective against other microorganisms 
(freezing, heating and chlorination) combined with prolonged asymptomatic viral shedding 
make norovirus extremely infectious and explain the extensiveness of outbreaks (Duizer et 
al., 2004a; Siebenga et al., 2008; Teunis et al., 2008; Widdowson et al., 2005). Additionally, 
repeated infections can occur throughout life with re-exposure, likely due to the lack of 
lasting immunity and the lack of complete cross-protection against the diverse norovirus 
strains.  (Donaldson et al., 2010; Patel et al., 2009). 
Over the past years, a global increase in the number of norovirus outbreaks was noticed, 
with the GII.4 variants being accountable for the vast majority of cases. These GII.4 variants 
have become globally predominant and were responsible for four pandemics in the last two 
decades (Lindesmith et al., 2008; Siebenga et al., 2008). This emergence of dominants strains 
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of norovirus causing worldwide epidemics suggests a pattern of epochal evolution 
resembling that of influenza (Glass et al., 2009).  
1.2 Host susceptibility and virus-host interaction 
Susceptibility to norovirus infection involves both acquired immunity and genetic resistance 
(Parrino et al., 1977). Volunteer studies found that some individuals were repeatedly 
susceptible to norovirus infection whereas others were repeatedly resistant (Parrino et al., 
1977). Although it was initially unclear why some subjects did not develop illness, current 
research suggests that host genotype is a prominent factor in the development of norovirus 
infection since it depends on the presence of specific human histo-blood group antigen 
(HBGA) receptors in the gut of susceptible hosts (Lindesmith et al., 2003). Infection by 
norovirus relies on the recognition of HBGAs in the initial viral attachment and this key 
event most likely controls host susceptibility and resistance to norovirus (Hutson et al., 2004; 
Marionneau et al., 2002; Tan & Jiang, 2005, 2011).  
HBGAs are complex carbohydrates linked to proteins or lipids on the surface of red blood 
cells and mucosal epithelia of the respiratory, genitourinary and digestive tracts, or present 
as free oligosaccharide in biological fluids such as milk and saliva. These antigens provide 
diversity within the human population and their biosynthesis is controlled by the enzyme 
products of alleles at the ABH, fucosyltransferase (FUT) 2, and FUT 3 loci (Hutson et al., 
2004).  
A number of distinct binding patterns of noroviruses to HBGAs have been described 
according to the ABO, Lewis and secretor types of the human HBGAs (Huang et al., 2003; 
Huang et al., 2005). This explains the correlation between secretor status and susceptibility 
to Norwalk virus infection, where secretor individuals with a wild-type FUT2 gene (~80% of 
the population), who express HBGAs on gut epithelial cells and in body fluids, are 
susceptible to Norwalk virus infection, while nonsecretors, with a null FUT2 allele, are 
completely resistant (Lindesmith et al., 2003).  
The binding patterns of noroviruses to HBGAs are currently sorted into three major groups, 
the H, the A/B, and the Lewis binding groups (Tan & Jiang, 2011). While norovirus strains 
display distinct HBGA binding properties, collectively they can infect nearly all individuals 
due to their high genetic variability (Le Pendu et al., 2006). This highlights the highly 
adaptive nature of noroviruses and the likelihood of a long co-evolution of human 
noroviruses with their human host.  
1.3 Classification and genome organization 
Noroviruses are a
 genetically diverse group of viruses belonging to the genus Norovirus of 
the family Caliciviridae (Green, 2007). The Norwalk virus was the first norovirus to be 
discovered and associated to a gastroenteritis outbreak in an elementary school in Norwalk, 
Ohio, USA in 1968 and is today considered the prototype of the genus Norovirus (Kapikian 
et al., 1972). 
The family Caliciviridae comprises, besides Norovirus, four accepted (Sapovirus, Lagovirus, 
Vesivirus, Nebovirus) and two tentative genera (Recovirus, Valovirus), that include human and 
non-human pathogenic viruses (Farkas et al., 2008; Green, 2007; Green et al., 2000; L'Homme 
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et al., 2009). The two genera Norovirus (NoV) and Sapovirus (SaV) are the only that comprise 
human pathogenic agents, both causing acute gastroenteritis. The other genera include 
important veterinary pathogens such as the rabbit hemorrhagic disease virus (RHDV) which 
causes an often fatal hemorrhagic disease in rabbits in the genera Lagovirus, the feline 
calicivirus (FCV) which causes a respiratory disease in domestic and wild cat species in the 
genera Vesivirus, and the Newbury-1 virus which infect bovines in the genera Nebovirus. The 
tentative genera Recovirus, comprises the Tulane virus (TV) isolated from stool samples of 
rhesus macaques whose pathogenicity remains to be elucidated (Farkas et al., 2008). The 
other tentative genera Valovirus comprises the St-Valérien-like viruses isolated from pig 
feces (L'Homme et al., 2009). 
Noroviruses are today classified into five genogroups (GI-V) divided into at least 31 genetic 
clusters or genotypes based on sequence diversity in the complete capsid protein VP 1 
(Zheng et al., 2006). Genogroups share > 60% amino acid identity in the VP 1 and each 
genetic cluster or genotype shares > 80% identity in amino acid sequence of VP 1 (Green et 
al., 2000; Zheng et al., 2006). Human noroviruses have been associated with GI, GII and GIV 
and bovine and murine noroviruses belong to GIII and GV, respectively (Wobus et al., 2004; 
Zheng et al., 2006). GII also contains swine strains and GIV comprises the feline (lion) and 
canine strains (Martella et al., 2007; Martella et al., 2008; Mesquita et al., 2010).  
Noroviruses are small icosahedric non-enveloped viruses of 27-32 nm with a positive-sense 
single stranded (ss) RNA genome of 7.4–7.7 kb, organized into three open reading frames 
(ORF1-3) (Fig 1). The 5’ proximal region of the norovirus genome encodes a polyprotein of 
six/seven nonstructural protein products in a single ORF (ORF1). ORF2 encodes the major 
structural capsid protein VP1 and ORF3 the minor structural protein VP2. Norovirus 
genome is covalently linked, at the 5’ end, to a viral protein called VPg (virion protein, 
genome-linked) and is polyadenlyated at the 3’ end (Green, 2007). 
The ORF1 of norovirus encodes the six/seven nonstructural proteins in the following order: 
the p48/ N-terminal protein (or NS1-2), the NTPase (NS3), the p22 (NS4), the VPg (NS5), the 
viral protease (Pro, NS6), and the viral RNA-dependent RNA polymerase (RdRp, NS7). 
Some of these proteins have defined activities such as NS3, an NTPase (nucleoside 
triphosphatase) (Pfister & Wimmer, 2001), NS6, a protease (Liu et al., 1996), and NS7, an 
RNA-dependent RNA polymerase (RdRp) (Fukushi et al., 2004; Rohayem et al., 2006a). 
Also, NS5 known as VPg, is a protein that is covalently attached to the 5’ ends of viral 
genomes in place of a typical 5’ cap and that can function as a primer in viral RNA 
replication (Burroughs & Brown, 1978; Rohayem et al., 2006b). The role of the remaining 
nonstructural proteins (NS1-2 and NS4) in norovirus replication is not yet well defined 
(Green, 2007). Available data suggests that NS1-2 and NS4, also known as N-term/p48 and 
p22, respectively, both contribute to norovirus replication complex formation on 
intracellular membranes, including that of the Golgi apparatus, and disrupt intracellular host 
protein trafficking (Ettayebi & Hardy, 2003; Fernandez-Vega et al., 2004; Hyde et al., 2009).  
The major structural protein of norovirus, the VP1, is encoded by ORF2. Virions contain 180 
copies or 90 dimers of VP1 that assemble into icosahedral particles (Prasad et al., 1999; 
Prasad et al., 1994). The VP1 protein is divided into a conserved internal shell domain (S) 
and a more variable protruding domain, the P domain, that forms the arch-like protrusions 
and is further subdivided into P1 and P2 domains (Fig. 1). The P2 subdomain is located at  
www.intechopen.com
 Targeting Norovirus: Strategies for the Discovery of New Antiviral Drugs 
 
125 
 
Fig. 1. Schematic representation of a viral particle and genome organization of norovirus. 
Genomic and subgenomic RNA of norovirus with the genome linked protein VPg at the 5’ 
end and the poly(A) tail at 3’ end is shown along with the nonstructural proteins (NS1-7) 
encoded by ORF1 as well as the structural proteins (VP1 and VP2), encoded by ORF2 and 3. 
See text for further details 
the outmost surface of the viral capsid and comprises a hypervariable region, where resides 
the binding interface for HBGA association with norovirus (Bu et al., 2008; Cao et al., 2007; 
Choi et al., 2008; Tan et al., 2003). The VP2 is a small, basic structural protein encoded by the 
ORF3 which is present in one or two copies per virion (Glass et al., 2000; Hardy, 2005). Its 
function in viral replication is currently undefined but there is evidence that it increases the 
level of expression of VP1 and stabilizes virus-like particles (VLPs, generated through 
expression of the VP1) (Bertolotti-Ciarlet et al., 2003). The basic charge of VP2 suggests that 
it may function in encapsidation of the viral genome (Karst, 2010). 
1.4 Replication of norovirus 
The replication of norovirus has not been yet fully elucidated and most of the current 
knowledge is drawn by analogy with other (+)ssRNA viruses and studies with related 
animal caliciviruses. Norovirus is one of the positive-sense ssRNA viruses whose genome 
functions directly as the mRNA, beginning the infectious cycle with the synthesis of a 
precursor that only gives rise to the nonstructural proteins, including the RdRp enzyme that 
transcribes then one subgenomic mRNA encoding the structural proteins (VP1 and VP2) 
(Green, 2007). Like the other (+)ssRNA viruses , the replication of norovirus occurs in the 
cytoplasm. In Fig 2 is represented a scheme of the replication of norovirus.  
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In the first step, the viral attachment of the virion to the cell receptor, the P2 subdomain of 
the VP1 binds to a sugar residue, mostly to the HBGA carbohydrates in the case of human 
noroviruses but also to sialic acid or heparan sulfate (Hutson et al., 2002; Marionneau et al., 
2002; Rydell et al., 2009; Stuart & Brown, 2007; Tamura et al., 2004; Taube et al., 2009). This 
interaction between VP1 and HBGA seems not to be enough for the entry of norovirus in 
host cells and the involvement of a membrane protein as a receptor or co-receptor for 
subsequent penetration/entry is suspected (Tan & Jiang, 2010). 
Norovirus enters the cell using a non-clathrin-, non-caveolin-mediated endocytic pathway 
but dependent on dynamin II and cholesterol (Gerondopoulos et al., 2010; Perry & Wobus, 
2010). Moreover, this entry step is pH-independent and no conformational changes in the 
capsid required for viral uncoating are observed with acidic intracellular pH (Perry et al., 
2009). 
After the internalization in the cell and uncoating of viral genome, the translation of ORF1 of 
the viral genomic RNA produces a large protein, the so called nonstructural polyprotein. 
The initiation of translation is dependent on the interaction of the VPg with the cellular 
translation initiation machinery (Daughenbaugh et al., 2003; Daughenbaugh et al., 2006). A 
co-translational processing releases the nonstructural proteins and their precursors 
(Sosnovtsev, 2010). The proteolytic processing is mediated by the viral protease (NS6) which 
is autocatalytically released from the polyprotein precursor (Putics et al., 2010).  
The replication of norovirus is believed to occur in a replication complex (RC) formed by 
intracellular membranous structures which contain all the viral nonstructural proteins along 
with host proteins that will help viral replication as well as the viral RNA intermediate, 
ssRNA and double stranded RNA (dsRNA) (Hyde & Mackenzie, 2010; Hyde et al., 2009). 
The recruitment of host membranes (RE, Golgi, endossomes) necessary for the formation of 
the RC, is induced by the viral non structural proteins p48 (NS1-2) and p22 (NS4), through a 
modulation of the host cell secretory pathway (Denison, 2008; Hyde & Mackenzie, 2010; 
Sharp et al., 2010).  
Once the RC is assembled, the RdRp (NS7) starts the synthesis of the antigenomic RNA 
(negative sense) from the genomic (positive sense) RNA template. The initiation of 
antigenomic RNA synthesis by the RdRp is dependent upon uridylylation of VPg that 
serves as a primer in the presence of the polyadenylated genomic RNA (Rohayem et al., 
2006a; Rohayem et al., 2006b). This antigenomic RNA is then used as a template for 
synthesis of the new genomic RNA and of the subgenomic RNA.  
The newly synthesized genomic RNA is either translated as a polyprotein precursor or used 
for packaging in the assembled viral protein core. The subgenomic RNA (positive sense) is 
translated as structural proteins, VP1 and VP2. Finally, the structural proteins are assembled 
and the genomic RNA packaged, followed by release of the mature virion from the cell. This 
late stages of replication are, however, poorly understood. 
1.5 Surrogate models for the study of human norovirus 
Human noroviruses are not cultivable in routine laboratory cell culture or primary tissue 
cultures (Duizer et al., 2004b). There has been a single report using a 3-D cell culture system 
demonstrated for the first time successful passage of both GI and GII norovirus in vitro 
www.intechopen.com
 Targeting Norovirus: Strategies for the Discovery of New Antiviral Drugs 
 
127 
 
 
 
Fig. 2. Replication scheme of norovirus and key events. 
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(Straub et al., 2007) but several independent laboratories failed to reproduce such results 
(Papafragkou et al., 2009). For this reason, the study of human norovirus has been made 
using surrogate viruses.  
Initially, surrogate models for norovirus infectivity included viruses from other genera 
within the family Caliciviridae, namely porcine enteric calicivirus, a Sapovirus, and the feline 
calicivirus (FCV), a Vesivirus (Doultree et al., 1999; Duizer et al., 2004a) (Fig.3).  
 
Fig. 3. Characteristics of the different surrogates models for human norovirus within the 
genera of the family Caliciviridae 
FCV was then frequently used as a surrogate model for survival, persistence and 
inactivation studies of human noroviruses until the more recent discovery of murine 
norovirus (MNV) (Bae & Schwab, 2008; Cannon et al., 2006; Wobus et al., 2004; Wobus et al., 
2006). MNV is a genogroup V norovirus and is to date the only Norovirus able to replicate 
both in cell culture and in a small animal model. Moreover, like human norovirus MNV is 
an enteric pathogen that spreads through the fecal-oral route and is shed at high levels in 
the feces (Karst et al., 2003; Wobus et al., 2004). On the other hand, the use of FCV was 
criticized because: (i) it does not belong to the genus Norovirus; (ii) it is a respiratory virus; 
(iii) it is not shed in feces and (iv) it cannot survive at low pH, a necessary characteristic of 
enteric viruses that must survive passage through the stomach (Bae & Schwab, 2008; 
Cannon et al., 2006; Duizer et al., 2004b; Wobus et al., 2006). Therefore, MNV is considered 
today the best surrogate model for human norovirus (Wobus et al., 2004; Wobus et al., 2006).  
MNV has the size, shape, and buoyant density characteristic of human norovirus (Green, 
2007; Karst et al., 2003). MNV genome has also the three ORFs characteristic of noroviruses 
(Wobus et al., 2006), but it has an additional ORF4 that overlaps ORF2 in a different reading 
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frame (Thackray et al., 2007). ORF1 of MNV also encodes the nonstructural proteins and 
ORFs 2 and 3 encode the two proteins of the the viral capsid (Sosnovtsev et al., 2006). The 
conserved molecular features of MNV and human norovirus genomes suggest that many 
fundamental mechanisms of replication are conserved between murine and human 
noroviruses (Wobus et al., 2006). Although MNV infection seems to be asymptomatic in 
immunocompetent mice, it causes diarrhea and lethality in mice deficient in components of 
innate immunity (Karst et al., 2003; Mumphrey et al., 2007). Hence, the clinical presentation 
of MNV is different from the one of human norovirus, and for this reason MNV does not 
constitute yet the ideal model for studying human norovirus.  
The recent discovery of the Tulane virus (TV), a novel calicivirus isolated from stool samples 
of rhesus macaques, together with the likelihood of this virus causing intestinal infection 
and the availability of a tissue culture system could make TV a valuable surrogate for 
human norovirus (Farkas et al., 2008). 
An alternative approach to the study of norovirus RNA replication was established when a 
human norovirus replicon-bearing cell line was created by transfecting a plasmid containing 
most of the Norwalk virus genome into mammalian cell lines (Chang et al., 2006). These cell 
lines are capable of constitutively expressing the replicative enzymes and other 
nonstructural proteins, allowing the study of RNA replication and providing a platform for 
screening antiviral compounds.  
Reverse genetics systems have been developed for some caliciviruses, namely for PEC, FCV, 
MNV and TV (Chang et al., 2005; Chaudhry et al., 2007; Sosnovtsev & Green, 1995; Ward et 
al., 2007; Wei et al., 2008; Wobus et al., 2004). These systems have helped to elucidate 
fundamental aspects of caliciviruses replication through the introduction of deliberate 
changes in certain genes and the analysis of the resultant effect in the virus phenotype. 
Reverse genetics systems represent also an important tool for the development of antivirals 
against norovirus (Putics et al., 2010).  
Virus-like particles (VLPs) which result of the independent expression and self-assembly of 
the VP1 are also valuable tools that have been used in many research areas of norovirus (El-
Kamary et al., 2010; Jiang et al., 1992). These VLPs are morphologically and antigenically 
indistinguishable from the native forms of viruses found in human stools, and retain the 
binding properties of native norovirus virions at least in terms of carbohydrate association 
(Jiang et al., 1992). VLPs have been used for the development of immunological assays, the 
study of virus-host interaction, structural studies of the norovirus capsid, investigation of 
antigenic relationships and as potential vaccine candidates (Green, 2007; Tan & Jiang, 2005). 
2. Strategies to inhibit the replication of norovirus 
The antiviral research of norovirus is still in its infancy and there are only few reports of 
antivirals for norovirus. Recently, a new chemical scaffold, the 2-styrylchromones, has 
shown anti-norovirus activity in the MNV surrogate model, opening the door to the search 
of anti-norovirus drugs among a wider range of novel compounds from different chemical 
families (Rocha-Pereira et al., 2010). Additionally, nitoxanide, a prodrug used to treat 
protozoal gastroenteritis has been reported to reduce the duration of norovirus 
gastroenteritis in a clinical trial although the mechanism of action remains unclear 
(Rossignol & El-Gohary, 2006). 
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In the following section, potential targets and strategies to inhibit norovirus life cycle are 
presented, based on the information available today on norovirus genome organization, 
functions of structural and nonstructural proteins, replication and virus-host interaction 
(Fig. 4). The predictable advantages and/or disadvantages of these strategies are discussed 
and some antiviral drugs previously identified as active against similar molecular targets in 
other plus stranded RNA viruses are suggested as a starting point.  
 
Fig. 4. Targeting the various steps of the replication of norovirus   
2.1 Targeting cellular receptors of norovirus  
Human noroviruses recognize HBGA carbohydrates present on cell surface, which are key 
players in the initial viral attachment, acting most likely as cellular receptors or co-receptors 
of norovirus (Hutson et al., 2002; Marionneau et al., 2002; Tan & Jiang, 2005, 2011)  
Noroviruses present diverse binding patterns to HBGAs, being currently sorted into three 
major binding groups, the H, the A/B, and the Lewis binding group (Tan & Jiang, 2011). 
The interaction between noroviruses and HBGA is highly strain-specific rather than 
genogroup- or genotype-specific (Tan & Jiang, 2010). Hence, strains of the H, A/B and 
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Lewis binding groups can be found in both two major genogroups of human noroviruses 
(GI and GII).  
The existence of only three HBGA-binding interfaces makes possible the design of antivirals 
against these targets in noroviruses. Any compound that targets a given HBGA binding 
interface may be capable of blocking infection of all strains that bind that same type of 
HBGA. Thus, only three different HBGA-binding interfaces would need to be targeted by 
compounds to block nearly all noroviruses in the GI and GII genogroups (Tan et al., 2009).  
The strategy of targeting this first step of virus-receptor interaction could be of great interest to 
use as prophylactic therapy since it would be effective in preventing infections of individuals 
in high risk settings or that were in contact with an index case during an outbreak (Tan & 
Jiang, 2008). Furthermore, it would be expected that such compounds would be able to reduce 
the severity of symptoms in already infected individuals and likely reduce virus excretion, 
limiting its propagation to higher numbers of individuals (Tan & Jiang, 2008). Citrate, and 
other glycomimetics, showed to have the potential to block human noroviruses from binding 
to HBGAs (Hansman et al., 2011) providing a starting point for norovirus inhibitors. 
However, there are predictable difficulties to this strategy, one of which being the fact that 
the early steps of norovirus life cycle are not yet fully disclosed. Recent findings of FCV and 
MNV binding to sialic acid (Rydell et al., 2009; Stuart & Brown, 2007; Taube et al., 2009) or 
heparan sulfate (Tamura et al., 2004) broadens the spectrum of sugar residues that interact 
with these viruses. Moreover, the identification of a membrane protein, the junctional 
adhesion molecule A (JAM-A), as a receptor for FCV (Makino et al., 2006) raises the 
hypothesis of this protein or other members of the Ig superfamily being also cellular 
receptors for caliciviruses, like they are for reoviruses and picornaviruses (Tan & Jiang, 
2010). According to the proposed model for reoviruses, the virus interact firstly with a sugar 
residue like sialic acid, as a determinant of tropism that is responsible for initial virus 
attachment, and later use a membrane protein (JAM-1) to enter the host cell (Barton et al., 
2001). The role of these two molecules in viral attachment and entry is likely to occur also in 
FCV, and one could even speculate that it could be extended to noroviruses since it is usual 
that viruses within the same family use similar cellular receptors (Tan & Jiang, 2010).  
Much remains to be unraveled in this field, therefore there are still doubts about the selection 
of the best target for chemical compounds to block or interfere with virus attachment.  
2.2 Targeting entry and uncoating of norovirus 
In order to enter host cells, viruses take advantage of cellular processes entering by an 
endocytic pathway, most commonly a clathrin-mediated endocytosis. Viral entry can also 
occur via caveolin-mediated endocytosis, clathrin/caveolin-independent endocytosis, 
macropinocytosis, or phagocytosis (Marsh & Helenius, 2006). After entrance in the host cell, 
the uncoating of virus must occur in order to deliver the viral genome into the host 
cytoplasm. This event is often triggered by the acidic environment of endosomes but it can 
also occur after the binding of virus to cellular receptors (Tsai, 2007). 
Studies with FCV showed this virus enters cells by clathrin-mediated endocytosis in a pH-
dependent manner (Stuart & Brown, 2007). However, it was demonstrated that the entry of 
MNV is clathrin/caveolin-independent but mediated by dynamin II and cholesterol 
(Gerondopoulos et al., 2010; Perry & Wobus, 2010). In addition, studies with MNV show this 
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virus is pH-independent and that a low intracellular pH does not trigger conformational 
changes in the capsid required for MNV uncoating (Perry et al., 2009). This difference in 
sensitivity to low pH between FCV and MNV was suggested to be related with the different 
routes of infection of these viruses (Perry et al., 2009). While MNV is an enteric virus that 
infects its host by the small intestine and retains infectivity for hours at a pH of 2 (similarly 
to the human Norwalk virus), FCV is a respiratory virus that significantly decreases 
infectivity at low pH (Cannon et al., 2006; Dolin et al., 1972). 
Further understanding of the cellular mechanisms of norovirus entry and uncoating would 
bring out new antiviral targets. 
2.3 Targeting structural proteins of norovirus 
The VP1 is the major structural protein of norovirus and its P2 subdomain, which is located 
at the outmost surface of the viral capsid, comprises the binding surface for HBGA (Bu et al., 
2008; Cao et al., 2007; Choi et al., 2008; Tan et al., 2003). The function of VP2 is currently 
undefined and there is not sufficient information to address this minor protein as an 
antiviral target.  
The search of compounds targeting VP1 of norovirus was explored through a saliva-based 
enzyme immunoassay (EIA) that measures their capacity to block the binding of norovirus 
VLPs to HBGAs present in such biological fluid (Feng & Jiang, 2007). Different chemical 
compounds were found to be strong inhibitors of this binding being potential candidates for 
further development as antivirals for norovirus (Feng & Jiang, 2007), but one should be 
aware that a saliva-based EIA was used instead of a cellular system or animal model and 
this could be regarded as an handicap. 
Antiviral drugs that target viral surface proteins of other RNA virus have been described, 
such as pleconaril, a picornavirus capsid-binding compound, but resulted in a not entirely 
successfully strategy (Field & Vere Hodge, 2008). The problem with this kind of drugs relies 
on their low genetic barrier since the viral surface proteins can undergo variations without 
compromising viral fitness, easily allowing resistant strains to emerge (Field & Vere Hodge, 
2008). The same problem would most likely take place with norovirus given its well known 
antigenic variation. A strategy could be the use of combination therapy of this class of 
compounds together with drugs against well conserved nonstructural proteins with critical 
functions. This would avoid or at least delay the development of resistance. 
2.4 Targeting nonstructural proteins 
The six/seven nonstructural proteins of norovirus are the p48/ N-terminal protein (NS1-2), 
the NTPase (NS3), the p22 (NS4), the VPg (NS5), the viral protease (Pro, NS6), and the viral 
RNA-dependent RNA polymerase (RdRp, NS7). Since noroviruses share some similarities 
with picornaviruses, the nomenclature and functions of these ORF1-encoded proteins of 
norovirus was initially predicted through comparative sequence analysis of their 
picornavirus counterparts. Hence, the norovirus RdRp was called 3D-like, the protease was 
called 3C-like, the p22 was called 3A-like, the NTPase was named 2C-like and the p48/N-
term was related to the 2B protein (Green, 2007). This resemblance could be important for 
the search of antivirals against norovirus since the known strategies and targets for 
inhibiting the replication of picornavirus might be also effective for norovirus.  
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Although a detailed knowledge of the role of nonstructural proteins is still not available, 
some important clues have raised from studies with MNV which showed that all these 
proteins play a role in norovirus replication and are associated with the replication complex 
(RC) and the viral RNA intermediate dsRNA (Hyde et al., 2009). There is also evidence that 
the replication complex of MNV is associated with host membranes, namely of the 
endoplasmic reticulum (ER), the Golgi apparatus and endossomes which suffer virus-
induced rearrangements (Hyde et al., 2009; Wobus et al., 2004). These and other features of 
each nonstructural protein are described below, as well as how these could be used for the 
discovery of antiviral drugs against norovirus. 
2.4.1 p48  
The role of p48 or NS1-2 is not yet well defined but it is thought to be comparable to that 
of the analogous picornavirus 2B protein, which participates in intracellular membrane 
changes that occur during virus replication (Sosnovtsev, 2010). Studies with Norwalk 
virus indicated that the p48 may interfere with disassembly of the Golgi complex and 
cellular protein trafficking (Ettayebi & Hardy, 2003; Fernandez-Vega et al., 2004) while 
studies with MNV and FCV point out that p48 is associated with the recruitment of ER 
membranes to the RC (Bailey et al., 2009; Hyde & Mackenzie, 2010). This recruitment of 
membranes is vital to the synthesis of new viral proteins by the actively replicating 
noroviruses (Hyde et al., 2009; Wobus et al., 2004). Hence, the impairment of the 
mechanisms controlled by p48 in the membrane rearrangements could be a good strategy 
to stop the norovirus life cycle. 
2.4.2 NTPase  
The NTPase or NS3 shares sequence motifs with other viral NTPases, namely the 
picornaviruses 2C protein and the flaviviruses NS3 helicase/NTPase. It has also been 
classified in the superfamily 3 of RNA helicases (Hardy, 2005; Pfister & Wimmer, 2001). The 
role of these enzymes consists in catalyzing the hydrolysis reaction of nucleoside 
triphosphates and using the released energy to unwind the viral nucleic acids (Kwong et al., 
2005). However, until now there is only experimental data confirming the NTPase but not 
the helicase activity of this nonstructural protein of norovirus (Hardy, 2005).  
In recent years, substantial efforts have been made to identify inhibitors of such proteins, 
since they are well conserved and essential for viral replication. The thiazolobenzimidazoles 
were identified as potent inhibitors of picornaviruses, showing one of these compounds, 
TBZE-029 [1-(2,6-difluorophenyl)-6-trifluoromethyl-1H,3H-thiazolo[3,4-a]benzimidazole] to 
target the protein 2C of coxsackievirus B3 (De Palma et al., 2008a; De Palma et al., 2008c). 
These and other picornavirus 2C-targeting compounds, such as MRL-1237 [1-(4-
fluorophenyl)-2-(4-imino-1,4-dihydropyridin-1-yl) methylbenzimidazole hydrochloride] 
and HBB [2-(ǂ-hydroxybenzyl)-benzimidazole] (De Palma et al., 2008a; De Palma et al., 
2008c; Norder et al., 2011) could as well be inhibitors of the NTPase of norovirus. The 
multiple mechanisms through which compounds could inhibit the helicase/NTPase have 
been extensively described elsewhere (Rohayem et al., 2010). The search of norovirus 
NTPase inhibitors could result in the development of an innovative antiviral strategy and at 
the same time reveal functional details of this enzyme of norovirus.  
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2.4.3 p22  
The function of p22 or NS4 in norovirus life cycle is also not yet fully understood. This 
protein occupies in norovirus genome a position similar to that of the 3A protein in 
picornavirus genomes but they share only limited sequence similarity (Green, 2007; Hardy, 
2005). The 3A protein is known to inhibit the protein trafficking from the ER to Golgi 
apparatus, a function central to the cellular homeostasis (Wessels et al., 2006). A similar 
function has been recently described for Norwalk virus p22 (Sharp et al., 2010). It was 
reported that this protein contains a well-conserved motif that mimics the normal ER export 
signal, leading to the inhibition of protein trafficking to Golgi, inducing its disassembly and 
ultimately inhibiting cellular protein secretion (Sharp et al., 2010). Since this motif is highly 
conserved in human noroviruses, it may constitute a new target for the design of anti-
norovirus drugs (Sharp et al., 2010).  
Besides, based on what has been described for picornavirus 3A protein, one of the 
consequences of the inhibition of cellular protein secretion by p22 could be a more severe 
infection due to the decrease of surface MHC class I proteins and normal cytokine release 
that leads to a reduction of clearance in infected cells (Sharp et al., 2010; Wessels et al., 2006). 
Additionally, there is evidence suggesting that p22 is part of the norovirus RC participating 
in the recruitment of membranes from the late secretory pathway (Golgi and endossomes) to 
the RC, being the main viral protein known to be responsible for the recruitment of 
endossome membranes (Hyde & Mackenzie, 2010). 
Two compounds, enviroxime and TTP-8307, have shown to inhibit the in vitro replication of 
enteroviruses and rhinoviruses by targeting the nonstructural protein 3A (De Palma et al., 
2009; Heinz & Vance, 1995). Therefore, these compounds are good candidates to be 
evaluated for their ability to inhibit p22 and the norovirus replication. 
2.4.4 VPg  
The VPg or NS5 is covalently linked to the 5’-end of the norovirus RNA genome and plays 
an important role in the replication of norovirus. Initiation of RNA synthesis by viral RdRp 
is dependent upon uridylylation of VPg that serves as a primer in the presence of the 
polyadenylated genomic RNA (Rohayem et al., 2006a; Rohayem et al., 2006b). This “protein-
primed” initiation occurs after the annealing of the elongated VPg-poly(U) to the poly(A) 
tail of the viral genome (Rohayem et al., 2006a; Rohayem et al., 2006b). 
The inhibition of this uridylylation step or prevention of annealing to the poly(A) tail 
through a disruption of interaction between VPg and the viral genome or the RdRp could be 
an effective manner to stop the norovirus life cycle and therefore a good antiviral strategy 
(Rohayem et al., 2010). 
It is known that the initiation of translation of norovirus proteins is dependent on the 
interaction of the VPg with eIF4F complex (eukaryotic initiation factor 4F), a key component 
of the cellular translation initiation machinery (Daughenbaugh et al., 2003; Daughenbaugh 
et al., 2006). The interaction of the VPg with individual eIF4F components has been 
described. A direct interaction with eIF4E (cap binding protein) was firstly demonstrated 
with the VPg of Norwalk virus (Goodfellow et al., 2005). A similar interaction with this 
component was also seen with FCV and MNV but, in these viruses, the key requirement for 
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RNA translation was shown to be the interaction with another component of the complex, 
the eIF4A (a RNA helicase) (Chaudhry et al., 2006). This was demonstrated by the inhibitor 
of eIF4A hippuristanol which blocked the translation of both FCV and MNV viral proteins 
in vitro (Chaudhry et al., 2006). However, the potential use of hippuristanol in therapy is 
limited by the fact that this compound is also an inhibitor of cellular protein synthesis, 
therefore expected to be cytotoxic. Panteamine is another compound that has the potential 
of interfering with VPg/ eIF4F complex, since it stimulates the helicase/NTPase activity of 
eIF4A, dysregulating its function within the eIF4F complex (Bordeleau et al., 2006). 
Therefore, these classes of compounds could potentially be explored as antivirals for 
norovirus but with less cytotoxic derivatives.  
2.4.5 Protease  
The norovirus protease or NS6 is a cysteine protease that is responsible for processing the 
nonstructural polyprotein precursor into the six/seven nonstructural proteins (Green, 2007). 
The atomic structure of the norovirus protease has been resolved (Nakamura et al., 2005). A 
two-domain structure was identified as being similar to other viral cysteine proteases, like 
those of picornavirus 3C proteases that show a chymotrypsin-like fold with a cysteine as the 
active-site nucleophile (Nakamura et al., 2005; Zeitler et al., 2006).  
Similarly to what happens with the picornavirus 3C protease, the scissile bonds of the 
calicivirus proteases are restricted to a few number of dipeptides, revealing a very high 
specificity of substrate recognition in the cleavage sites of these enzymes which have also 
shown to be highly conserved among all caliciviruses (Sosnovtsev, 2010). Hence, the 
development of substrate-like peptides that block the protease active site constitutes an 
interesting strategy to inhibit the protease of norovirus. The inhibitors of the 3C protease of 
picornavirus, such as ruprintrivir, may potentially inhibit the norovirus protease given the 
overall similarity between the proteases of these viruses. (Binford et al., 2005; De Palma et 
al., 2008c; Leyssen et al., 2008). 
The detailed structural information available for norovirus protease constitutes a good basis 
for the rational design of protease inhibitors and a valuable tool for the in silico screening of 
large compound libraries (Tan & Jiang, 2008). The recent development of functional assays 
for the detection of protease activity of calicivirus, using fluorogenic substrate peptides 
(Zeitler et al., 2006) or bioluminescence technologies (Oka et al., 2011) can constitute useful 
tools for the screening of protease inhibitors.  
However, the role of norovirus protease appears to be more extensive. An association of the 
protease of MNV with mitochondria was suggested since they were found to co-localize 
within the cell (Hyde & Mackenzie, 2010). In this case, the protease could be implicated in 
an up-regulation of apoptosis of norovirus, which is known to occur via a mitochondrial-
mediated apoptotic pathway involving caspase-9 (Bok et al., 2009). The involvement of viral 
protease with apoptotic pathways has been described for their picornavirus counterparts 
(Drahos & Racaniello, 2009). An association of proteases with mitochondria was linked, in 
hepatitis A and C viruses, to a cleavage of the mitochondrial antiviral signaling protein 
(MAVS) (Yang et al., 2007). Since MAVS induces antiviral responses of interferon and NF-
kB, one may implicate viral proteases in prevention of immune signaling (Hyde & 
Mackenzie, 2010).  
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Whether the protease of MNV plays a role in prevention of immune signaling through the 
cleavage of MAVS is currently under investigation (Hyde & Mackenzie, 2010). It is known 
so far that the innate immune response against MNV starts with the recognition of viral 
RNA by MDA-5 (McCartney et al., 2008), the cytosolic receptor which initiates the antiviral 
signaling cascade by interacting with MAVS, its downstream partner.  
In conclusion, targeting protease may be one of the most promising approaches to inhibit 
norovirus replication given the important function of this protein. 
2.4.6 RNA-dependent RNA polymerase  
The RdRp or NS7 is the central enzyme of replication, being responsible for the synthesis of 
the genomic, subgenomic and antigenomic RNA of norovirus. Given its critical role in 
norovirus replication, the RdRp constitutes one of the most important antiviral targets.  
The crystal structure of the norovirus RdRp in an enzymatically active form has been 
resolved and overall showed catalytic and structural elements characteristic of RdRp of 
other positive stranded RNA viruses (Ferrer-Orta et al., 2006; Nakamura et al., 2005; Ng et 
al., 2004). However, its carboxyl terminus folds into the active site cleft of the enzyme which 
constitutes a distinctive aspect of the norovirus RdRp deserving special attention when 
designing an RdRp inhibitor (Hardy, 2005; Ng et al., 2004). It would be expected that a 
compound that could interrupt the interaction between the carboxyl-terminus and the active 
site cleft of the RdRp would hamper norovirus replication (Tan & Jiang, 2008).  
A more accurate picture of how the RdRp of Norwalk virus functions was provided recently 
when the crystal structure of the Norwalk virus polymerase was resolved bound to the RNA 
primer template and to its natural substrate, a nucleoside triphosphate (NTP) (Zamyatkin et 
al., 2008). This ternary RdRp·RNA·NTP complex revealed details underlying the nucleotidyl 
transfer reaction, which is thought to be highly conserved among viral polymerases. This 
complex was also resolved bound to a potent inhibitor of picornavirus polymerases, the 5-
nitrocytidine triphosphate (NCT), revealing differences between NCT and NTP complexes, 
which indicate a novel mechanism of inhibition of the RdRp that should be explored in the 
design of anti-norovirus compounds mimicking natural nucleosides and nucleotides 
(Zamyatkin et al., 2008). 
A functional assay was developed for the detection of norovirus RdRp activity (Rohayem et 
al., 2006a; Rohayem et al., 2006b) and the inhibitory activity of some nucleoside analogs such 
as 2’-arauridine-5’-triphosphate and 3’-deoxyuridine-5’-triphosphate has been reported 
(Rohayem et al., 2010). Nucleoside analogs display similar mechanisms of inhibition of 
RdRps and some, like 2’-C-methylcytidine, 2'-C-methyladenosine and 4’-azidocytidine have 
shown a broad spectrum of activity against plus stranded RNA viruses, such as 
picornavirus and HCV (De Palma et al., 2008b; Goris et al., 2007; Klumpp et al., 2006). 
Hence, this class of compounds has great potential to be inhibitors of the norovirus RdRp 
and ought to be studied as antiviral drugs.  
Ribavirin is a guanosine analogue with broad-spectrum activity against RNA virus. 
Although it was discovered over 30 years ago, its mechanism of action still remains 
controversial. Ribavirin was formally approved to treat chronic HCV infections in 
combination with pegylated interferon and in aerosol form to treat pediatric respiratory 
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syncytial virus (RSV) infections (Graci & Cameron, 2006). It has also been used against a 
number of other viruses such as Lassa fever virus, Crimean Congo hemorrhagic fever, 
hantaviruses and severe acute respiratory syndrome coronavirus (SARS-CoV) (Haagmans & 
Osterhaus, 2006; Leyssen et al., 2008). Ribavirin has shown to be active against norovirus in 
the Norwalk replicon model and the MNV model (Chang & George, 2007). The main 
mechanism of action in the Norwalk replicon model was associated with the depletion of 
GTP in the cells since the addition of guanosine moderately reversed the antiviral effect of 
ribavirin (Chang & George, 2007). This depletion of intracellular GTP could be due to the 
inhibition of the cellular inosine monophosphate dehydrogenase (IMPDH) by ribavirin 
(Graci & Cameron, 2006; Leyssen et al., 2005). Mycophenolic acid (MPA), a potent 
noncompetitive inhibitor of IMPDH, also showed to inhibit Norwalk virus replication 
(Chang & George, 2007). 
Another of the proposed mechanisms of ribavirin is an increased mutation frequency via 
incorporation of ribavirin into newly synthesized genomes leading to error catastrophe 
(Graci & Cameron, 2006). However, ribavirin seemed not to induce catastrophic mutations 
in norovirus since there was no increase in the mutation rates in the ribavirin-treated 
Norwalk replicon-bearing cells (Chang & George, 2007).  
Overall, this data indicates that ribavirin or its analogs, such as EICAR (5-ethynyl-1-ǃ-D-
ribofuranosylimidazole-4-carboxamide) and viramidine, could constitute a promising 
starting point in the development of inhibitors of norovirus replication.  
2.5 Targeting the norovirus genome 
The norovirus RNA genome or viral transcripts also constitute an important target to inhibit 
the replication of norovirus. Antisense oligonucleotides and siRNAs (small interfering RNA) 
can be designed to target conserved regions of the norovirus genome with the aim of 
disrupting viral replication. For that, these oligonucleotides need to fulfill some requisites, 
namely the target sequence has to be involved in viral replication, accessible for 
oligonucleotide hybridization and conserved among different viral strains (Spurgers et al., 
2008). 
The existence of conserved secondary structures among calicivirus genomes opens the 
possibility of designing an oligonucleotide that would present a broad spectrum activity 
among noroviruses or troughout the family Caliciviridae. These conserved structures 
include 5’ terminal stem-loops, 3’ terminal hairpins, a stem-loop just upstream of the 
ORF1/2 junction in the antigenomic strand and a stem-loop at the 5’ end of the 
polymerase coding region with a motif characteristic of picornavirus cis-acting replication 
elements (cre elements) that dictate VPg uridylylation (Simmonds et al., 2008; Victoria et 
al., 2009). Some of these structures were found to be critical for the replication of MNV 
and for its infectivity (Simmonds et al., 2008). By using MNV reverse genetics system it 
was demonstrated that the disruption of the 5’-stem loops or the 3’-hairpins strongly 
impaired MNV replication in vitro (Simmonds et al., 2008). Moreover, a polypyrimidine 
tract located at the 3’-end of the genome has been incriminated in regulating viral fitness 
and virulence of MNV in vivo (Bailey et al., 2010). The important roles played by these 
conserved RNA structures in norovirus replication and virulence makes them potentially 
good antiviral targets.  
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The 5′-UTR (untranslated region) sequence of the norovirus genome has already been 
successfully targeted by an antisense strategy. A panel of peptide-conjugated 
phosphorodiamidiate morpholino oligomers (PPMOs) specific for the 5′-UTR of MNV 
proved to be effective in inhibiting its replication in vitro (Bok et al., 2008). Also, a consensus 
PPMO (designated Noro 1.1), designed to target the corresponding region of several diverse 
human norovirus genotypes, inhibited Norwalk virus protein expression in replicon-bearing 
cells (Bok et al., 2008). Moreover, PMOs targeting the 5′-UTR of the FCV genome were used 
successfully in three clinical trials during FCV outbreaks in kittens (Smith et al., 2008). 
Overall, these studies suggests that PPMOs directed against the relatively conserved 5′-end 
of the norovirus genome may show broad antiviral activity against this genetically diverse 
group of viruses and might translate into a successful clinical application but only further 
studies in animal models will say. 
An alternative nucleic acid-based strategy is the use of RNA interference (RNAi) for 
silencing the viral genome. A wide range of viruses have been inhibited with RNAi 
(Leonard & Schaffer, 2006) and concerning calicivirus the first preliminary results have been 
published (Bergmann & Rohayem, 2010; Rohayem et al., 2010). In this study, siRNAs 
targeting the 5’-UTR and the subgenomic region of the FCV genome were successful in 
inhibiting FCV replication in vitro, namely by reducing infectivity, reducing the levels of 
viral genomic RNA and inhibiting viral translation.  
2.6 Other strategies to stop norovirus replication 
The enhancement of the host cell’s antiviral mechanisms may constitute a valuable strategy 
to inhibit norovirus replication. Interferons (IFNs) are critical components of the innate 
immune response which establish an antiviral state of cells through interactions with IFN 
receptors expressed in nearly all nucleated cells. The binding of IFNs to their receptors 
triggers activation of STATs (signal transducer and activator of transcription) and cascade 
events which results in the induction of various antiviral proteins, such as RNA-dependent 
protein kinase (PKR) and RNase L (Samuel, 2001). However, many viruses are armed with 
anti-IFN mechanisms, such as those counteracting the STATs and inhibiting IFN synthesis 
(Samuel, 2001). 
Interferons, both type I (IFN-ǂ) and type II (IFN-Ǆ), showed to inhibit the replication of 
norovirus in the Norwalk replicon model (Chang & George, 2007; Chang et al., 2006). Norwalk 
virus did not present a strong anti-IFN mechanism in the replicon-bearing cells, and this may 
be a reason for its high sensitivity to IFNs (Chang & George, 2007; Chang et al., 2006). It was 
also demonstrated that IFN responses were critical to control MNV infection in vivo and 
inhibited viral replication in vitro (Karst et al., 2003; Wobus et al., 2004). Both type I and type II 
IFNs block the translation of viral proteins of MNV but while type II IFN-mediated inhibition 
is dependent on the well-characterized interferon-induced antiviral molecule PKR, type I IFN-
mediated inhibition occur through a PKR-independent process (Changotra et al., 2009). This 
data suggests that IFN may be a good therapeutic option for norovirus gastroenteritis. 
The cellular pathway of cholesterol biosynthesis has been shown to be upregulated during 
the replication of several viruses, including HIV and HCV (Giguere & Tremblay, 2004; Ye, 
2007). A study using Norwalk replicon system demonstrated that cholesterol pathways 
were also important in the replication of norovirus (Chang, 2009). Statins, such as 
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simvastatin and lovastatin, are well known drugs that interfere with cholesterol pathways 
by inhibiting de novo synthesis of cholesterol through inhibition of HMG-CoA (3-hydroxy-3-
methyl glutaryl-coenzyme A), reducing plasma cholesterol levels by upregulating low 
density lipoprotein receptor (LDLR) and promoting the uptake of LDL bound cholesterol to 
cells. It has been demonstrated that the use of statins resulted in a reduction of HCV 
replication through blockage of protein geranylgeranylation and the proper formation of 
viral replicase complexes (Ye, 2007; Ye et al., 2003). On the contrary, the inhibition of 
cholesterol biosynthesis using statins significantly enhanced the replication of Norwalk 
virus which was correlated with an increased expression of LDLR (Chang, 2009). It was 
postulated that LDLR could play an important direct role in virus replication such as 
participating in viral replication complexes as an essential cofactor (Chang, 2009). 
The activity of acyl-CoA:cholesterol acyltransferase (ACAT) is also an important factor for 
cholesterol biosynthesis. Unlike statins, treatment with ACAT inhibitors such as Cl-976, 
Sandoz 58-035, YIC-C8-434 and pyripyropene resulted in reduced levels of Norwalk 
replication and interestingly, in reduced levels of LDLR (Chang, 2009). This data indicate 
that ACAT may be a novel target for inhibiting norovirus replication and its inhibitors could 
be further developed as anti-norovirus drugs. 
3. Final remarks  
Antiviral therapy is still not available today for norovirus and certainly a long road still lies 
ahead. A significant progress has been made in the elucidation of the replication strategy of 
norovirus, for which the use of surrogate viruses, the generation of a Norwalk replicon 
model, the available crystal structures of norovirus proteins were landmark developments 
that helped this giant pursuit.  
In this chapter, we review and speculate about potential targets and antiviral strategies. 
Many were the targets suggested, however we believe that priority should be given to viral 
enzymes of replication, such as the RdRp and protease. Besides being key enzymes in 
norovirus life cycle, they are conserved across this genetically diverse group of viruses and 
divergent enough from cellular enzymes for their inhibitors to have good selectivity and 
minimal toxicity. Moreover, viral enzymes of replication are in general less prone to 
variation than structural proteins, minimizing the emergence of drug resistance.  
As the understanding of norovirus replication deepens, one could look forward to new 
opportunities for the development of innovative antiviral strategies targeting this important 
human pathogen in a near future.  
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